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tors predicting improved survival; however in a multivariable
model, achieving a CR1 (p¼0.002) and undergoing allogeneic
SCT retained prognostic signiﬁcance (p¼0.01).
Conclusion: Leukemic transformation from CMML is asso-
ciated with poor outcomes. For eligible patients, induction
chemotherapy followed by allogeneic SCT seems to offer the
best chances for achieving durable remissions.217
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complete remission (CR1) has become a standard of care for
many patients (pts) with intermediate or high risk acute
myeloid leukemia (AML). Furthermore, pts with relapsed
AML may be salvaged by re-induction and subsequent
alloSCT. Here, we analyzed the outcome of pts with AML
transplanted beyond CR1 at our center between 1996 and
2013.
Pts and Methods: 120 pts (50 female, 70 male) with a me-
dian age of 49 (19-72) years were retrospectively analyzed as
of June 30th, 2013. 92 pts had de novo AML and 28 pts had
secondary or therapy-related AML. 63 pts were in CR2
whereas 57 pts were refractory to re-induction therapy and
had active disease at the time of alloSCT. The SWOG/ECOG
cytogenetic risk proﬁle was favorable in 16 pts, intermediate
in 53 pts, and unfavorable in 34 pts (unknown: 11 pts, un-
determined: 6 pts). Conditioning consisted of a 12 Gy TBI-
basedmyeloablative regimen (MAC) in 51 pts. 61 pts received
reduced intensity conditioning (RIC: FLU/BU/ATG) and 9 pts
were conditioned using the FlamsaRIC protocol. A matched
related donor was available in 33 pts. 62 pts had a matched-
unrelated donor and 25 pts had a mismatched unrelated
donor.
Results: After a median follow-up of 39 (3-185) months, 44
pts are alive and in CR. Causes of death were relapse in 37 pts
or non-relapse mortality (NRM) in 36 pts. At 1, 3, and 5 years
after alloSCT projected overall survival (OS) or disease-free
survival (DFS) of the entire cohort was 50% (41-60%), 40%
(30-50%), and 39% (29-49%) or 48% (39-58%), 39% (30-49%),
or 38% (28-47%). At the same time points the cumulative
incidence of relapse (CIR) or NRM (CINRM)was 25% (19-35%),
31% (23-41%), and 32% (24-42%) or 25% (21-38%), 28% (21-
38%), or 30% (22-40%). In univariate analysis pts refractory to
re-induction therapy had a signiﬁcantly lower 3-year DFS
(26%) as compared to pts transplanted in CR2 (54%) (HR 1.8
(95%CI: 1.1-2.8), p¼0.01), due to an increased relapse rate
(40% vs 24%, p¼0.003). Similarly, an interval of 12 months
from diagnosis to alloSCT was predictive for a lower 3-year
DFS as compared to an interval of >12 months (21% vs 52%)
(HR 2.0 (95%CI: 1.2-3.3), p¼0.002), due to an increased
relapse incidence (47% vs 23%, p<0.001). All other factors
examined, i.e. gender, cytogenetic risk, AML subtype, age
group, type of conditioning, donor, or year of alloSCT, were
not predictive for OS, DFS, CIR, or CINRM. In multivariate
analysis, remission status and time from diagnosis to trans-
plantation were identiﬁed as independent prognosticators
for OS, DFS, and CIR.
Conclusions: In sum, our data indicate that pts with AML
beyond CR1 may be successfully salvaged by alloSCT. In
particular, pts transplanted in CR2 beneﬁt the most. Pts re-
fractory to re-induction may be candidates for alloSCT as
well. However, these pts have a poorer outcome due to a high
relapse rate irrespective of the cytogenetic risk proﬁle and
the conditioning regimen used.218
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Introduction: Patients with acute myeloid leukemia (AML)
refractory to induction chemotherapy have dismal progno-
ses. Although allogeneic stem cell transplant (allo-SCT)
Abstracts / Biol Blood Marrow Transplant 20 (2014) S151eS164 S155remains the only curative therapy for primary refractory
AML, there have been sparse reports regarding the outcome
of cord blood transplantation (CBT) for the population.
Patients and methods: We retrospectively reviewed
patients diagnosed as primary refractory AML who under-
went CBT at our institute from Mar. 2003 to June 2013
consecutively.
Results: Seventy-seven patients were included in this study.
Underlying diseases were de novo AML in 50 (65%) and AML-
MRC in 27 (35%). Forty-nine (61%) were male and 30 (39%)
were female. Their median age was 59 years (range 19-72).
The number of prior chemotherapy was 1 course in 28 (36%),
2 in 30 (39%), and more than 3 in 19 (25%), respectively.
Median time from diagnosis to transplantation was 162 days
(range; 64-1539). TBI+Cy/Bu+Cy was used as pretransplant
conditioning regimen in 4 patients, Flu+Mel80+TBI4 in 23,
Flu+Bu16+Mel80 in 26, Flu+Bu16+TBI2-4 in 12, and other RIC
regimens in 12. Nineteen patients died before engraftment.
Among the remaining 58 patients, 42 achieved neutrophil
engraftment with a median of 21 days post-transplant
(range; 13-45). Nine patients received urgent 2nd CBT for
primary graft failure (n¼6) or early disease relapse (n¼3).
Among the 42 evaluable patients, 36 (86%) developed acute
GVHD of grade II or higher, including 11 (26%) patients who
developed that of grade III or IV. Of the 36 patients who
survived longer than 100 days post-transplant, 21 patients
developed chronic GVHD, including 13 with limited and 8
with extensive form. With a median observation time for
survivors of 16.5 months (range; 3-94), 2 year overall sur-
vival (OS) and disease free survival (DFS) were 31.4% and
22.4%, respectively. Cumulative incidences of relapse and
non-relapse mortality (NRM) at 2 years post-transplant were
35% and 42.2%, respectively. In univariate analysis, patients
with aged 19-60 showed superior OS at 2 years compared to
elderly patients (>61 years) (44.8% vs 16.4% p¼0.013).
Relapse rate was signiﬁcantly higher in the elderly compared
to those with aged 19-60 (50.5% vs 21.7%, P<0.01), whereas
NRM did not differ between the two groups (43.3% vs 40.2%,
P¼0.87). Eighteen patients died of disease relapse and 36
died of NRM, including graft failure (3), infection (20),
bleeding (2), organ failure (4), TMA (3) and idiopathic
pneumonia syndrome (4).
Conclusion: Our results suggested that CBT is a feasible and
promising treatment approach for patients with primary
refractory AML. Optimal strategies for decreasing relapse
especially in the elderly should be established to improve the
outcome.219
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Introduction: Cytogenetic changes that accompany the
relapse of myeloid neoplasms after allogeneic hematopoietic
cell transplantation (HCT) have not been well studied. The
goal of our study is to evaluate the frequency and spectrum
of the cytogenetic change that occurs at relapse of myeloid
malignancies after HCT and evaluate the impact on
prognosis.
Methods: We performed a retrospective review of all pa-
tients who relapsed following an allogeneic HCT for a
myeloid malignancy. Cytogenetic ﬁndings at diagnosis and atrelapse were compared. Cytogenetic studies were performed
according to conventional methods.
Results: Of 212 patients transplanted for a myeloid malig-
nancy between 03/2004-01/2013, 43 relapsed (34AML,
1CML, 4MDS and 4MPN) at a median time of 113 days (range
22-820 days). Cytogenetic ﬁndings at relapse were different
from diagnosis in 14/43 patients (32.5%). The mean number
of cytogenetic alterations/patient increased from 1.09 at
diagnosis to 1.51 at relapse. The majority (10/14) represented
clonal evolution deﬁned as acquisition of more complex
abnormalities. This group includes 3 patients with normal
karyotype at diagnosis and 7 patients who originally showed
one, two, or complex abnormalities. All of these 10 patients
developed complex abnormalities (deﬁned as >3 abnor-
malities). Other than clonal evolution, new-onset chromo-
somal abnormalities unrelated to diagnosis were seen in
three patients, two of which acquired a more favorable
cytogenetic proﬁle than at diagnosis (inverted chromosome
16 and a single abnormality in a patient with complex
karyotype at diagnosis, respectively). One patient with
normal karyotype AML acquired a donor-derived del(20q)
abnormality.
Conclusions: Cytogenetic change is common at relapse of
myeloid neoplasms after HCT and is associated with an
increasing cytogenetic complexity. The acquisition of more
unfavorable cytogenetic proﬁles likely contributes to poor
outcomes. Exceptions to this trend are patients that acquire
more favorable cytogenetic features than at diagnosis,
resulting in potentially better response to therapy and longer
survival. The signiﬁcance of donor-cell-derived del(20q), a
rare recurrent cytogenetic abnormality in the post-trans-
plant setting, is not clear.220
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